Pre-made Tabalumab benchmark antibody ( Whole mAb, anti-TNFSF13B therapeutic antibody, Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-540

Pre-Made Tabalumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-540-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Tabalumab biosimilar, Whole mAb, Anti-TNFSF13B Antibody: Anti-BAFF/BLYS/CD257/DTL/TALL-1/TALL1/THANK/TNFSF20/TNLG7A/ZTNF4 therapeutic antibody
INN Name Tabalumab
TargetTNFSF13B
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesEli Lilly
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMultiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus
Development Techna